Ivonescimab · AK-112, SMT-112

What is Ivonescimab?

Ivonescimab is a bispecific antibody that binds PD-1 on T cells and VEGF, blocking PD-1 signaling so that T-cell inhibition is reduced, and blocking VEGF binding to VEGFR to inhibit angiogenesis. It is studied in multiple solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, colorectal, urothelial, salivary gland and small cell lung cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

AK-112, SMT-112, Pemetrexed, Carboplatin, Akeso

Drug type

Bispecific antibody

Targets

Programmed cell death protein 1 (PDCD1), Vascular endothelial growth factor (VEGFA)

Mechanism

Immune activation, directed at Programmed cell death protein 1 (PDCD1) and Vascular endothelial growth factor (VEGFA)

Pathways

VEGF/VEGFR signaling, tumor angiogenesis, T-cell activation

Therapy area

Oncology

Developer

Akeso

In trials of

SMMT

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 3

UNII

Y0O332CU66

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Adenoid Cystic CarcinomaAdvanced Salivary Gland CarcinomaExtensive Stage Lung Small Cell CancerMetastatic Colorectal CancerMetastatic Salivary Gland CancerMetastatic Urothelial CarcinomaMetastatic Urothelial Carcinoma (UC)Non-Small Cell Lung CancerNon-Squamous Non-small Cell Lung CancerSalivary Gland CancerSquamous Cell Carcinoma Head and Neck Cancer (HNSCC)

Other drugs acting on PDCD1 / VEGFA

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT05382442
• ClinicalTrials.gov NCT06396065
• ClinicalTrials.gov NCT06396065
• ClinicalTrials.gov NCT06767514

Updated Oct 11, 2026.